https://www.selleckchem.com/pr....oducts/ssr128129e.ht
During the prospective safety data collection period (median 7.6 months) among patients with prospective follow-up (N = 75), POM-related adverse event incidence rate was 42.7% (serious 18.7%; grade ≥ 3 hematological POM-related adverse events 8.0%). Only neutropenia (13.3%) was reported at a frequency ≥10%. In conclusion, in this real-world study, POM/LoDex displayed a long PFS with no new safety signals emerging.This study aimed to establish a rapid in vitro plant regeneration method from rhizome buds of Kaempferia parviflora to o
Like
Comment
Share
